A clinical trial conducted by Novos found that its core intervention was associated with improvements in key cardiovascular health measures among aging adults, according to the company. The study evaluated changes in blood pressure, cholesterol and other established risk factors over a defined period.
Novos reported that participants experienced statistically significant reductions in both systolic and diastolic blood pressure as well as improvements in lipid profiles compared with baseline measurements. The company said these outcomes suggest potential heart health benefits linked to its core programme, which integrates personalised lifestyle and metabolic support.
The trial also monitored additional parameters such as waist circumference and markers of metabolic function, with results indicating positive trends across multiple indicators commonly associated with cardiovascular risk. Novos stated that the findings align with its emphasis on comprehensive approaches to age‑related risk reduction that extend beyond isolated biomarker changes.
According to the company, the clinical research was conducted with adults aged 40 and older and involved structured interventions designed to support adherence to dietary, physical activity and metabolic optimisation strategies. Novos claims the outcomes may reflect broader benefits of its programme for reducing risk factors tied to cardiovascular disease.
The company noted plans to share detailed data with the broader scientific community as part of ongoing efforts to validate and refine its longevity‑focused interventions. The findings contribute to growing interest in multimodal strategies for managing age‑related health risks and supporting long‑term wellbeing.
